Reunion Neuroscience to Present at Upcoming November Conferences
October 31 2022 - 7:30AM
Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) ("Reunion" or
the “Company”), a biopharmaceutical company committed to developing
innovative therapeutic solutions for underserved mental health
conditions, announced today that the Company will participate in
two upcoming conferences in November.
Hanson Wade
5th Annual Neuropsychiatric &
Psychedelics Drug Development Summit
Moderator: Greg Mayes, President & CEO,
Reunion Neuroscience Format: Panel Discussions
- Topic: Guiding Development Strategy to Secure
Company Longevity
- Date and Time: Tuesday, November 1 at 9:30 a.m. ET
- Topic: Reflection on Hallucinations &
Impact on Efficacy to Guide Development
- Date and Time: Tuesday, November 1 at 3:45 p.m. ET
Jefferies London Healthcare
ConferenceSpeakers: Greg Mayes, President
& CEO, Nathan Bryson, Chief Scientific Officer, Reunion
NeuroscienceFormat: Presentation
- Track 7 - Room: Westminster, Entresol Level
- Date & Time: Wednesday, November 16, at 12:55 - 1:25 p.m.
GMT
A webcast of the presentation is accessible via
this link: https://wsw.com/webcast/jeff255/reun/1868886. The
webcast will also be archived on the ‘Events & Presentation’
section of the Reunion website.
Management will also take part in one-on-one
meetings over the duration of the Jefferies London Healthcare
conference. Institutional investors interested in scheduling a
meeting with Reunion’s management team, or for more information on
the conference, please contact KCSA Strategic Communications at
Reunion@kcsa.com.
About Reunion Neuroscience Inc.
Reunion (formerly, Field Trip Health Ltd.) is committed to
developing innovative therapeutic solutions for mental health
conditions. The Company’s lead asset, RE-104 (previously known as
FT-104), is a proprietary, novel serotonergic psychedelic compound
being developed as a potential fast-acting and durable
antidepressant for patients suffering from post-partum and
treatment resistant depression. Reunion is also developing the
RE-200 series, which includes compounds with potential for more
selective serotonin receptor activity with reduced psychoactivity
for potential use in more chronic treatment paradigms and
indications.
Learn more at
https://www.investors.reunionneuro.com, and
https://www.reunionneuro.com.
Follow us on LinkedIn, Twitter and
Instagram.
To be added to the Reunion Neuroscience email
list, please email Reunion@kcsa.com with “REUN” in the subject
line.
Cautionary Note Regarding
Forward-Looking Information This release
includes forward-looking information (within the meaning of
Canadian securities laws and within the meaning of the United
States Private Securities Litigation Reform Act of 1995) regarding
the Company and its business. Often but not always, forward-looking
information can be identified by the use of words such as "expect",
"intends", "anticipated", "believes" or variations (including
negative variations) of such words and phrases, or state that
certain actions, events or results "may", "could", "would" or
"will" be taken, occur or be achieved. Such statements are based on
the current expectations and views of future events of the
management of the Company and are based on assumptions and subject
to risks and uncertainties. Although the management of believes
that the assumptions underlying these statements are reasonable,
they may prove to be incorrect. The forward-looking events and
circumstances discussed in this release may not occur and could
differ materially as a result of known and unknown risk factors and
uncertainties affecting the companies. Although the Company has
attempted to identify important factors that could cause actual
actions, events or results to differ materially from those
described in forward-looking statements, there may be other factors
that cause actions, events or results to differ from those
anticipated, estimated or intended. Accordingly, readers should not
place undue reliance on any forward-looking statements or
information. No forward-looking statement can be guaranteed. Except
as required by applicable securities laws, forward-looking
statements speak only as of the date on which they are made and the
Company does not undertake any obligation to publicly update or
revise any forward-looking statement, whether as a result of new
information, future events, or otherwise. Additional information
relating to the Company, can be located in its continuous
disclosure documents available on the SEDAR website at
www.sedar.com and on the EDGAR section of the SEC’s website at
www.sec.gov.
Neither Toronto Stock Exchange, or its
Regulation Services Provider, have approved the contents of this
release or accept responsibility for the adequacy or accuracy of
this release.
Media Contact:Shana
Marino KCSA Strategic Communications(347)
487-6189reunion@kcsa.com
Investor Contacts:Phil Carlson
/ Sophia BashfordKCSA Strategic Communications(646) 573-0776 /
(929) 246-7307reunion@kcsa.com
Reunion Neuroscience (TSX:REUN)
Historical Stock Chart
From Nov 2024 to Dec 2024
Reunion Neuroscience (TSX:REUN)
Historical Stock Chart
From Dec 2023 to Dec 2024